hrp0092p2-23 | Adrenals and HPA Axis | ESPE2019

"Girls with Idiopathic Premature Adrenarche Achieve Normal Adult Height"

Javier Mejorado-Molano Franciso , Pérez-Segura Pilar , Gómez-Aragón Isabel , Collado-Valiente Rosa , Gómez-Neo Ana , Gavela-Pérez Teresa , Soriano-Guillén Leandro

Introduction: Studies about pubertal onset and the menarcheal age in girls with the antecedent of idiopathic premature adrenarche (IPA) are limited and with discordant results. For these reasons, we created a cohort of girls with the diagnosis of IPA. The objectives of our study were: a) to know the age of pubertal onset; b) to evaluate menarcheal age; c) to determine the growth rate in the first two years after the IPA diagnosis; d) to collect adult height da...

hrp0095p1-482 | Fat, Metabolism and Obesity | ESPE2022

Liraglutide SC in the treatment of severe obesity in Pediatrics: a missed therapeutic opportunity?

Diez-Lopez Ignacio , Sarasua-Miranda Ainhoa , Jose Espina-Diez Mari

Liraglutide 3.0 mg has been shown to improve body mass index (BMI) and weight in obese adolescents. And it has done so in a randomized, double-blind, phase 3 clinical trial that has investigated the effect of liraglutide 3mg. compared with placebo for weight control in 251 obese minors, and as a complement to a healthy lifestyle. Adverse events associated with the use of liraglutide 3.0 in pediatric patients are not very different from those observed in adults. There may be ca...

hrp0095p2-50 | Diabetes and Insulin | ESPE2022

Inhaled glucagon, a new well-accepted therapeutic tool in pediatrics

Diez-Lopez Ignacio , Sarasua-Miranda Ainhoa , José Espina-Diez Maria

On 01/14/2021, the European Commission authorized the marketing of Baqsimi® 3 mg (nasal glucagon), a powder medicine, ready to be used, in the treatment of severe hypoglycemia in adults, adolescents and children over four years of age with diabetes mellitus. Baqsimi® is the first and only nasal glucagon treatment available approved in the European Union (EU), and has been designed as a rescue treatment in cases of severe hypoglycemia, being absorbed passively into the ...

hrp0095p2-87 | Diabetes and Insulin | ESPE2022

100 years with insulin. Implementation of analogs and technology in our environment

Diez-Lopez Ignacio , Sarasua-Miranda Ainhoa , José Espina-Diez Maria

Almost 100 years ago, a major turning point in the life expectancy of people with diabetes around the world was reached with the discovery of insulin. In 1936, Hagedorn had the ingenious idea of combining insulin with a protein, protamine, and zinc and his NPH was used almost mainly in pediatrics until the end of 2003, when glargine U100 made its appearance.Objective: To evaluate the clinical experience in the incorporation of different ...

hrp0086p2-p95 | Adrenal P2 | ESPE2016

Early Adrenarche: A Common Query but not Easily Resolved

Sarasua Ainhoa , Diez-Lopez Ignacio

Introduction: Early/advanced adrenarche is a frequent reason for consultation in Children Endocrinology.Objectives: To evaluate the number and characteristics of cases of early/advanced adrenarche referred for assessment to the Children’s Consultation Endocrinology in the period between January 2015 and December 2015.Results: In this period are rated 522 first consultations of which 39 (7%) have been prematurely adrenarche. In...

hrp0086p2-p769 | Pituitary and Neuroendocrinology P2 | ESPE2016

Novel Uses of Psychiatric Drugs to Treat Hypothalamic Obesity

Julian Maria Cristina Azcona San , Gomez-Cardenas Francisco Javier Aguilar , Falconi Jose Luis Leon , Elicegui Amaia Ochotorena , de las Heras Ana Navedo , Lamban Ana Catalan , Martin Patricia Sierrasesumaga , de Almiron Monica Prados Ruiz , Martin Eduardo Arnaus

Background: Hypothalamic obesity (HyOb) is a disease characterized by weight gain resistant to lifestyle changes and dietary restriction. The main clinical findings are hyperfagia and decline of satiety, high levels of insulin and an increase of adipogenesis. The major problem for these patients is that conventional treatments, either medical or surgical are not succesful and have variable results.Objective and hypotheses: We aim to describe the natural ...

hrp0092lb-20 | Late Breaking Posters | ESPE2019

Introduction of Flash Glucose Monitoring in Children with Type 1 Diabetes: Experience of a Single-Centre in Spain

Leiva-Gea Isabel , Garcia Vázquez Javier , Rocío Liñán Jurado Francisca , Angel Maese Ruiz Miguel , Jiménez Hinojosa Jose , Pedro López-Siguero Juan

Flash glucose monitoring is now included in the Portfolio of Services of the Public Health System of Andalusia in Spain. We enrolled 145 paediatric T1D diabetes patients into a prospective, interventional study of the impact of the FreeStyle Libre system on HbA1c levels in this population, as well as additional measures of glycemic health, such as Time in Range (TIR) and Time Below Range (TBR). Subjects were trained in use of the FreeStyle Libre system at the start of the stud...

hrp0089p3-p139 | Fat, Metabolism and Obesity P3 | ESPE2018

Lymposomal Acid Lipase Deficit in Patients with Hypercholesterolemia

Diez-Lopez Ignacio , Sarasua Ainhoa , Lorente Isabel

The deficit of lysosomal acid lipase (LAL) is an infrequent (1: 40,000–300,000 prevalence), autosomal recessive, monogenic pathology. It can aggressively (Wolman’s disease): malabsorption and severe dyslipidemia with survival less than one year of life. The cholesterol ester storage disease (CESD) presents with dyslipidemia, liver disease and early cardiovascular disease.Goals: Descriptive study of the prevalence of LAL deficiency and carriers ...

hrp0086p2-p96 | Adrenal P2 | ESPE2016

Assessment of Clinical Effectiveness and Safety of Using Flutamide in Children with Pre-menarche Hierperandrogenismo

Diez-Lopez Ignacio , Sarasua Ainhoa , Lorente Isabel

Today we have an increase in patients with early-ahead forecast pubarche with impaired bone carving for advancement but organicidad criteria (HSC) but if dysfunction or adrenal hyperandrogenism and/or ovarian There are several anti-androgen drugs, all without usual pediatric use (use ‘of label’). Low-dose flutamide 62.5 mgr/day has been postulated as a treatment in these cases, but its use is restricted due to the risk of side effects (gynecomastia and liver involvem...

hrp0086p2-p284 | Diabetes P2 | ESPE2016

The Implementation of a System of Continuous Monitoring of Blood Glucose and Open (FREE STYLE FREE) Improves Metabolic Control of Affected Children DMtipo1

Diez-Lopez Ignacio , Saraua Ainhoa , Lorente Isabel

It is known that more checks of blood glucose, metabolic control of patients with type 1 suffering Dm improvement. Improved technology has made it possible to develop devices interstitial glucose control both blinded (retrospective) and open (in real time). The FREE STYLE free device is the latest appearance on the Spanish/European market. Although initially not seem indicated in <18 th, these are the a priori more could benefit from an improvement of metabolic control.</p...